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ABSTRACT 
T cells are one of the body’s main defenses against viruses and cancers and are therefore 
considered to play a major role in immunotherapies after stem cell transplantation and in 
HIV-1 vaccine and cure strategies. However, malignancies and chronic viral infections, such 
as HIV-1, eventually cause the T cells to become dysfunctional, resulting in a loss of control. 
As the T cell population is highly heterogeneous, studying the characteristics of the relatively 
few cells that are specifically recognizing infections and malignancies is of immense 
importance to fully understand what makes up an effective T cell response. Therefore, the 
aim of this thesis has been to evaluate the single-cell characteristics of T cells using 
microwell-chip based imaging and multi-color flow cytometry. 
The cytokine IL-2 is widely used to expand T cells for immunotherapy, but it also leads to 
expansion of the regulatory T cells (Tregs) that dampen the desired T cell response. We 
evaluated the effects of addition of IL-7, which previously was shown to decrease Treg 
expansion, to the protocol by monitoring the actions of T cells with single-cell resolution in a 
microwell chip. Addition of IL-7 did not affect the migration properties or cell-cell 
interactions, however it increased T cell survival in the microwell chip. Overall, the 
microwell chip was proved to be suitable for T cell studies and addition of IL-7 was 
confirmed to be beneficial when preparing T cells for immunotherapy. 
During HIV-1 infection, CD8+ T cells become exhausted, i.e. upregulate inhibitory receptors 
in a process linked to the loss of functional properties, due to the constant antigen burden. We 
found that the transcription factors T-bet and Eomes were inversely expressed on bulk and 
HIV-specific CD8+ T cells. Cells with a high expression of Eomes and a low expression of T-
bet were linked to an increased expression of inhibitory receptors, a transitional memory 
phenotype and a loss of functional capacity. This transcriptional profile remained after more 
than 10 years of treatment, suggesting that this might contribute to an inability of HIV-
specific CD8+ T cells to control the infection even during successful treatment. 
We continued by investigating the role of a novel inhibitory receptor, T cell immunoglobulin 
and ITIM domain (TIGIT), on CD8+ T cell exhaustion during HIV-1 infection. TIGIT was 
upregulated on bulk and HIV-specific CD8+ T cells and was linked to an increased 
expression of markers of exhaustion and immune activation as well as a T-betdimEomeshi 
transcriptional phenotype. Furthermore, upregulation of TIGIT on HIV-specific CD8+ T cells 
was linked to the downregulation of its complementary co-stimulatory receptor CD226 and a 
diminished functional capacity. Finally, expression of the TIGIT/CD226 ligand PVR was 
upregulated of T follicular helper cells, representing a major source of latent and productive 
HIV-1 infection. The result suggests that PVR is upregulated on HIV-infected cells and 
provides another major obstacle for HIV cure strategies.  
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1  INTRODUCTION 
1.1 INTRODUCTION TO T CELLS 
T cells, or T lymphocytes are cells of the adaptive immune system. All T cells express the T 
cell receptor (TCR), which recognizes antigens, i.e. peptides cleaved from proteins that can 
be either self-derived or derived from pathogens or malignant processes. These peptides are 
presented by the major histocompatibility complex (MHC) molecules (in humans called 
human leukocyte antigen (HLA)). The two main groups of T cells are the CD8+ T killer cells 
(also called cytotoxic T cells (CTL)) and the CD4+ T helper cells. The TCR alone is not 
enough for T cells to recognize antigen presented by HLA molecules, in addition a co-
receptor is needed to stabilize the TCR. For CD8+ T cells this is the cluster of differentiation 
8 (CD8) molecule, which together with the TCR recognizes antigens presented by HLA class 
I molecules, which are present on all nucleated cells in the body (Fig. 1). In turn, CD4+ T 
cells express the CD4 molecule that together with the TCR recognizes antigen presented on 
HLA class II molecules that are present on professional antigen presenting cells (APC), such 
as dendritic cells, monocytes and B cells. The HLA-molecules are the most polymorphic 
genes in the human body. The HLA class I gene is further divided into HLA-A, -B and -C 
alleles and the HLA class II gene can be further divided into HLA-DP, -DQ and -DR. Each 
allele is in turn present in different isoforms, making sure that the T cells are able to combat a 
broad variety of pathogens. 
 
 
 
 
 
Figure 1. CD8+ T cell recognition of an infected cell. The TCR, together with the CD8 molecule on the CD8+ 
T cell recognizes a viral peptide presented by a HLA class I molecule on the surface of the infected cell. TCR: T 
cell receptor; HLA: Human leukocyte antigen; CD8: Cluster of differentiation 8. 
1.1.1 T cell development 
All T cells arise from the same common ancestor stem cells in the bone marrow and then 
migrate to the thymus where they undergo maturation. The maturation process involves T cell 
education where the cells are required to pass two tests. First is the positive selection, which 
ensures that the TCR is able to recognize HLA molecules. Cells that fail this test will not 
receive the necessary survival signals and will die by neglect. The second test is the negative 
selection, during which the TCR is presented with a HLA molecule presenting a self-derived 
antigen. If the cell reacts to this complex too strongly there is a risk it will cause autoimmune 
reactions, therefore these cells are deleted. After passing both of these tests, the T cell 
HLA class I
CD8
TCR
CD8+ T cell Virus infected cell
Viral peptide
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“graduates” and is allowed to leave the thymus and enter the lymphatic tissues as a naïve T 
cell in order to scan the body for foreign antigens. 
1.1.2 CD8+ T cells 
CD8+ T cells are the killer cells of the adaptive immune system. They recognize peptides 
presented by HLA class I molecules on cells infected with intracellular pathogens such as 
viruses and cancer cells. Naïve CD8+ T cells that have not encountered their cognate antigen 
circulate through the secondary lymphoid tissues; lymph nodes, mucosa-associated lymphoid 
tissue (MALT), gut-associated lymphoid tissue (GALT), tonsils, spleen and Peyer’s patches. 
In these tissues the naïve CD8+ T cells make contacts with professional APCs and when 
encountering their specific antigen, they receive signals to proliferate and mature into effector 
T cells that can be either short-lived effector cells or long-lived memory precursor effector 
cells (reviewed in [1]). These cells leave the lymphoid tissue and travel through the blood 
into the site of the infection. Here, the CD8+ T cells form immune synapses with the infected 
target cells, through which they secrete granules containing perforin and granzymes. Perforin 
creates a pore in the surface of the target cell allowing for granzyme B to enter the cell and 
interact with caspases that cause the target cell to undergo apoptosis, thus eliminating the 
infected cell (reviewed in [2]). Furthermore, CD8+ T cells produce a number of cytokines that 
are essential for containment of an infection such as interferon gamma (IFN-γ), tumor 
necrosis factor (TNF) and interleukin-2 (IL-2). When an infection is cleared most virus-
specific CD8+ effector cells die by apoptosis and less than 10% of the cells remain to create a 
pool of long-lived memory cells ready to quickly become activated in case of reinfection [3] 
(Fig. 2).  
 
Figure 2. CD8+ T cell response against a virus. When a naïve CD8+ T cell recognizes its cognate peptide 
presented by a dendritic cell (DC), it becomes activated and starts maturing and dividing to produce a massive 
number of effector CD8+ T cells. The effector CD8+ T cells recognize infected cells and secrete cytotoxic 
granules in order to kill the infected cells and clear the infection. When the antigen is eliminated the effector 
cells are no longer needed and the majority die by apoptosis whereas a small fraction form a memory CD8+ T 
cell pool. 
CD4+ T helper cell Virus infected cell
Virus infected 
cell
Naive CD8+ T cell
Expansion of activated 
CD8+ T cells
Secretion of cytotoxic granules
and cytokines
Target cell death
Clearance of infection
Formation of memory 
CD8+ T cells
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Several cell surface markers are used to define the memory phenotype of T cells; CD45RO 
and/or CD45RA which are isotypes of the CD45 molecule that augments signaling through 
the TCR, the lymph node homing marker CCR7 and the co-stimulatory receptors CD27 and 
CD28 [4, 5]. In this thesis we have used CD45RO, CCR7 and CD27 to determine the 
phenotype of T cells (Table 1). 
 
 
 
 
Table I. CD8+ T cell maturation phenotypes based on expression of CD45RO, CCR7 and CD27. CM: central 
memory; TM: transitional memory; EM: effector memory; Eff: terminally differentiated effector; CD27+: CD27 
single positive. 
1.1.3 CD4+ T cells 
CD4+ T cells, also called T helper cells are as their name implies involved in helping other 
cells of the immune system to combat pathogens. The CD4+ T cells come in many different 
flavors including; Th1, Th2, Th17, T regulatory cells (Tregs) and T follicular helper (Tfh) 
cells, and their functions will be described below.    
The CD4+ Th1 cells drive the adaptive immunity pathway that combats intracellular antigens 
and cancer mainly by production of IFN-γ, IL-2 and IL-12 whereas CD4+ Th2 cells drive the 
humoral immunity pathway that promotes antibody production by B cells and responses 
against extracellular pathogens, such as parasites and bacteria, through production of IL-4, 
IL-5 and IL-10 [6]. Tfh cells are another type of T helper cells that are defined by their 
expression of the transcription factor Bcl-6, the chemokine receptor CXCR5, and a high 
expression of PD-1 [7, 8]. CXCR5 allows the Tfh cells to enter the B cell follicles of the 
lymph node, where T cells generally do not have access, in order to aid B cell development 
and immunoglobulin (Ig) production [7, 9]. CD4+ Th17 cells are pro-inflammatory cells 
involved in maintenance of mucosal barriers and in pathogen clearance in the mucosa [10]. 
The Tregs suppress the immune response by producing anti-inflammatory cytokines such as 
IL-10, TGF-β and IL-35 and by cytolysis of target cells [11]. These cells are of importance 
when it comes to switch off the immune response after a cleared infection to prevent the 
immune system from damaging healthy cells.     
1.1.4 Regulation of T cells 
T cell responses need to be regulated by different signals in order to match the situation the 
immune system is faced with. This is achieved by activating/inhibitory receptors and 
transcription factors. 
 Naive CM TM EM Eff CD27+ 
CD45RO
O 
- + + + - - 
CCR7 + + - - - - 
CD27 + + - - - + 
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1.1.4.1 Activating and inhibitory signals 
Binding of the TCR to a HLA:peptide complex results in a signaling cascade that in the end 
stages induces transcription factors that regulate gene expression. In addition to 
TCR/HLA:peptide binding, a second activating signal is required for sufficient signaling. 
This is provided by co-stimulatory receptors such as CD28, CD27 [12], ICOS, CD40L [12] 
and CD226 (DNAM-1) [13] that signal to the T cell to proliferate, produce cytokines and 
promote survival in order to combat the pathogen.  
After the clearance of an infection, the immune responses need to be turned off in order to 
prevent damage to the surrounding tissues. This is regulated by co-inhibitory receptors, which 
can inhibit TCR signaling. The most studied ones are programmed death-1 (PD-1) and 
cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) (reviewed in [14]). Other co-
inhibitory receptors involved in regulation of T cells are LAG-3, Tim-3, BTLA, CD160, 2B4 
(CD224) ([14]) and T cell immunoglobulin and ITIM domain (TIGIT) [15, 16]. The exact 
mechanisms by which these co-inhibitory receptors dampen immune responses are not 
known but studies have shown that they can induce inhibitory genes and modulate T cell 
signaling downstream of the TCR. Some inhibitory receptors such as CTLA-4 and TIGIT 
share a ligand with their co-stimulatory counterparts, CD28 and CD226 respectively, and can 
outcompete the co-stimulatory receptor for binding to the ligand [16, 17].  
Both co-stimulatory and co-inhibitory receptors are required in order to retain a balance in the 
immune system and avoid damage to the tissues or autoimmune reactions. This delicate 
balance is of key to maintain a functional immune system, something that is put out of play 
during chronic viral infections and cancer where the antigen persists.  
1.1.4.2 Interleukins 
Interleukins are a group of cytokines of the gamma-chain cytokine family. They have a 
number of different functions on the cells of the immune system, which they exert when 
binding to their cognate receptors on cells. IL-2, IL-7 and IL-15 are considered the central 
regulators of T cell populations as they all induce proliferation and promote survival of 
different T cell subsets [18].  
IL-2 is a T cell growth factor, produced by T cells in order to induce their proliferation. It has 
an important role on Treg proliferation and thus in the maintenance of peripheral tolerance. 
IL-2 binds to the IL-2 receptor (IL-2R), which is upregulated by IL-2, IL-7 and IL-15 as well 
as by antigen exposure [18].  
IL-7 is involved in expansion and maintenance of T cells both in the periphery and in the 
thymus. It is constitutively produced by stromal cells in the lymphoid tissues. The IL-7R 
(CD127) is expressed on mature naïve T cells in peripheral blood and thus helps maintain the 
homeostasis of naïve T cells. Central memory T cells expressing the IL-7R are maintained 
only through IL-7R signaling without the requirement for TCR signaling thus maintaining the 
memory T cell pool [18]. 
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IL-15 expands the effector memory T cells. Unlike IL-2 and IL-7 that are always secreted, 
IL-15 can also function through a membrane-bound isoform. Furthermore the IL-15R can be 
shed from cells and to block the active cytokine, making IL-15 use in immunotherapies rather 
complicated [18]. 
There are a number of other cytokines of importance for T cell functions. For example, IL-21 
induces proliferation of T cells, whereas IL-4 induces differentiation of CD4+ T cells into 
Th2. IL-17 is produced by Th17 cells and induces cytokine production and has a pro-
inflammatory function. IL-23 in turn induces proliferation of Th17 cells. Furthermore, there 
are cytokines with immune suppressing functions, such as IL-10 that inhibits cytokine 
synthesis and suppresses macrophage functions and IL-35 that has an immunosuppressive 
function [18]. 
1.1.4.3 Transcription factors 
Transcription factors are nuclear proteins involved in the process of gene transcription. For 
CD8+ T cells, the T-box transcription factors T-bet and Eomesodermin (Eomes) are of key 
importance, although additional transcription factors are also implicated for T cell 
development such as BLIMP1, NFAT, BATF, VHL, FOXO1 and FOXP1 [19]. The function 
of T-bet is to regulate the formation of terminally differentiated effector cells during an acute 
infection, whereas Eomes is responsible for generating the central memory cell pool in the 
end stages of the infection [19]. However, when an infection becomes chronic T-bet 
expression decreases whereas Eomes expression increases, resulting in a population with low 
T-bet and high Eomes expression (T-betdimEomeshi) that is associated with increased 
expression of inhibitory receptors and decreased functionality. In contrast, the more 
functional T-bethiEomesdim population, associated with a lower expression of inhibitory 
receptors ([19] & Paper II) decreases during chronic infection. Interestingly, T-bet has been 
shown to repress PD-1 expression by binding to the PD-1 regulatory region, and to regulate 
expression of LAG-3 and CD160 [20]. Thus the imbalance in the expression of these 
transcription factors during chronic viral infections could partially explain why the CD8+ T 
cells fail to contain chronic viral infections. 
1.2 T CELLS IN DISEASE 
The fields of HIV and cancer research might be viewed as two widely separate fields of 
research, but there are significant similarities between the two. Both in HIV infection and 
cancer, T cells have a very important role in eradicating the virus or the malignant cells, but 
fail to do so and eventually become dysfunctional. This part will first give a brief introduction 
to hematopoietic malignancies and in the second part a more detailed description of HIV 
infection.  
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1.2.1 Hematopoietic malignancies  
It is beyond the scope of this thesis to go into the field of hematopoietic malignancies in 
detail, but as Paper I deals with expansion protocols of T cells for immunotherapies after 
hematopoietic stem cell transplantation, a brief introduction will be given to this field.  
1.2.1.1 Hematopoietic malignancies 
Hematopoietic malignancies are cancers that affect the cells of the immune system. This 
group involves leukemia, Hodgkin’s lymphoma, Non-Hodgkin’s lymphoma, multiple 
myeloma and a number of less common blood cancers. They are a result of an abnormal 
differentiation of white blood cells resulting in a high number of malignant cells, which enter 
the blood. In order to replace the malignant cells hematopoietic stem cell transplantation 
(HSCT) is required. 
1.2.1.2 Hematopoietic stem cell transplantation 
During a HSCT the malignant blood cells of the patient are replaced with cells from a healthy 
donor that genetically matches the recipient [21, 22]. The first step of a HSCT is to treat the 
patient with radiation- and/or chemotherapy in order to clear the majority of the tumor cells 
and to create space for donor cells. After the initial treatment the patient receives stem cells 
from a donor. If the transfusion is successful, the donor’s immune system will be accepted by 
the host’s immune system and finally replace it entirely. However, HSCT is always 
associated with risks; the host cells can attack the foreign donor cells (host-versus-graft 
reaction) or the donor’s immune cells attack the host (graft-versus-host reaction) (reviewed in 
[23]). Both reactions are potentially life threatening. Therefore, patients receive 
immunosuppressive therapy before and after the transplant in order to avoid these reactions. 
Unfortunately this, in combination with the fact that it takes time for the new immune cells to 
establish in the host, leaves the patient vulnerable for opportunistic infections which might be 
life threatening. Therefore, strategies are needed to restore the immune system of the 
transplantation recipients. Among these are transfusions of T cells that can combat the 
pathogens causing opportunistic infections. These cells can be derived from the patient’s own 
cells (autologous) or from a genetically matched donor (allogeneic), which will be discussed 
in detail in section 1.3.  
1.2.2 Human immunodeficiency virus 
1.2.2.1 The history of HIV 
In the early 1980’s clinicians in the United States noticed an increase in the occurrence of 
lethal cases of opportunistic diseases and rare forms of cancer in a group of previously 
healthy patients [24, 25]. The disease was named acquired immunodeficiency syndrome 
(AIDS) [26]. The causative agent of AIDS remained unknown until 1983 when human 
immunodeficiency virus type 1 (HIV-1) was isolated from an AIDS patient [27, 28]. Later 
on, the origins of HIV-1 were traced back to a strain of simian immunodeficiency virus (SIV) 
found in West Central African chimpanzees [29]. Transmission of SIV from monkeys to 
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humans likely occurred in the beginning of the 20th century [30] resulting in the ongoing 
HIV-1 epidemic, which was fueled by the increased mobility and traveling habits of humans 
in the later part of the 20th century. Human immunodeficiency virus type 2 (HIV-2), a less 
virulent and less transmissible strain of HIV, was identified in 1986 [31].  HIV-2 was 
transmitted to humans from sooty mangabeys during the first half of the 20th century [32, 33]. 
HIV-2 is mainly present in parts of West Africa and in Portugal that have colonial ties to 
West-Africa, however HIV-1 remains the major cause of the epidemic. 
HIV-1 is divided into the subgroups M (major), O (outlier), N (non-M/non-O) and P [34]. Of 
these the M group is further divided into the subtypes A, B, C, D, F, G, H, J, K and a number 
of circulating recombinant forms (CRFs) [35]. Subtype C is the major cause of the epidemic 
in many parts of Africa, whereas subtype B is the dominant form in Western Europe, the 
Americas and Australasia and CRF01_AE and subtype B are the dominant subtypes in Asia 
[36]. 
* The term “HIV” will be used to refer to HIV-1 throughout this thesis unless otherwise 
stated 
1.2.2.2 Epidemiology of HIV 
According to the 2015 UNAIDS report [37] 36.9 million people are currently estimated to be 
living with HIV and of these approximately 15.8 million receive treatment. Due to recent 
successes in antiretroviral treatment (ART) strategies and major prevention programs in 
affected countries, the number of new HIV infections is steadily decreasing in many 
countries. However, in the Middle East, North Africa, Eastern Europe and Central Asia there 
has been an alarming development of increased numbers of new HIV infections since 2000. 
Worldwide, 2 million people were newly infected with HIV and 1.2 million died of AIDS-
related causes in 2014. Furthermore, according to the report it is estimated that 17.1 million 
people living with HIV do not know their HIV-positive status, which is a major risk factor for 
spread of the disease [37].  
1.2.2.3 The HIV genome  
HIV is a lentivirus belonging to the family of retroviruses. The main characteristic of 
retroviruses is the insertion of their genetic material into the host cell DNA, after which the 
cell will produce new virus particles as a part its normal activity. The genetic material of HIV 
consists of two single strands of positive-sense RNA that encode nine genes which can be 
divided into three groups; the retrovirus specific genes; gag, pol, env, the essential regulatory 
proteins tat and rev and the accessory regulatory proteins nef, vpr, vif, and vpu [38]. 
The group-specific antigen (gag) gene encodes for the Gag p55 protein, which is further 
cleaved into structural proteins; the capsid protein Gag p24, the matrix protein Gag p17, the 
nucleocapsid Gag p7 and the spacer peptide Gag p6. The polymerase (pol) gene encodes for 
the enzymes reverse transcriptase (RT) that transcribes viral RNA to DNA, integrase (IN) 
that integrates the viral DNA into the host genome and protease (PR) that cleaves viral 
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polyproteins into mature functional proteins. The envelope (env) gene encodes for the 
glycoprotein gp160, which is cleaved in order to produce the envelope proteins gp120 and 
gp41 that make up the viral spikes present on the virion surface that are involved in the 
insertion of the virus into a host cell. The HIV genome also consists of two essential 
regulatory proteins: transcriptional transactivator (tat) and regulator of virion gene expression 
(rev), which are important for viral gene expression. Additionally, there are four accessory 
regulatory proteins: negative regulatory factor (nef), viral protein r (vpr), viral protein u (vpu) 
and viral infectivity factor (vif) that are primarily involved in pathogenicity and immune 
evasion [38]. 
1.2.2.4 Structure of HIV 
The HIV RNA is surrounded by the viral capsid, which also contains the viral enzymes RT, 
IN and PR. The matrix that lines the surface of the virion further stabilizes the virus structure. 
The surface of the virion is composed of a lipid bilayer, taken from the host cell, together 
with the viral proteins gp120 and gp41 that form spikes on the envelope and are involved in 
HIV entry into target cells [38] (Fig. 3). 
 
 
 
 
 
 
 
Figure 3. The structure of HIV-1. The HIV-1 RNA and the viral enzymes are surrounded by the viral capsid 
that in turn is contained within a lipid bilayer lined by the matrix. The surface of HIV-1 is covered with viral 
spikes made up by the gp120 and gp41 proteins. RT: reverse transcriptase; PR: protease; IN: integrase, ssRNA: 
single-strand RNA. 
1.2.2.5 HIV life cycle 
HIV enters host cells expressing the CD4 receptor, which is present on CD4+ T cells, 
dendritic cells, macrophages and brain microglia. In addition, HIV requires expression of a 
co-receptor (CCR5 or CXCR4) in order to enter a cell [39, 40]. The process begins when the 
HIV protein gp120 binds to the CD4 receptor and undergoes a conformational change that 
allows insertion of gp41 to into the host cell membrane (Fig. 4). This enables the virion to 
fuse with the host cell and to release the viral nucleocapsid containing viral RNA, enzymes 
and molecules into the cytoplasm. HIV RNA is transcribed by the viral RT into DNA that is 
transported to the nucleus where it is integrated into host DNA by use of the viral protein IN. 
After this, HIV RNA and proteins are produced as a part of the host cell’s normal machinery. 
In order to produce new viral particles, the viral RNA and proteins are assembled near the 
Matrix
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cell surface after which the virus buds out of the cell, taking a part of the cell’s membrane 
with it. The maturation process continues after the virion has left the cell as the gag-pol 
polyprotein is cleaved by protease in order to create a fully mature virion that is ready to 
infect a new host cell [38] (Fig. 4). 
 
Figure 4. HIV life cycle. Reprinted with permission from [41]. 
1.2.2.6 HIV disease progression 
HIV is mainly transmitted via blood through a sexual route, intravenous drug use, mother to 
child (during pregnancy, delivery or breastfeeding) and transfusion of blood components. The 
virus is also present in semen and vaginal fluid, although at lower levels than in blood [42, 
43].  
HIV disease progression is divided into three stages; acute infection, chronic infection and 
AIDS (Fig. 5). During the acute phase, there is an intense production of virus resulting in a 
peak in the viral load (VL) in blood. It is during this phase that some patients get flu-like 
symptoms [44]. The CD8+ T cell response against HIV appears approximately three weeks 
after the initial infection coinciding with a decrease in the VL [45, 46] that finally reaches a 
plateau, called the viral set point [47]. During this time the first antibodies targeting HIV are 
produced, however in contrast to CD8+ T cell responses, they have very little impact on 
viremia during this phase [48]. This is the start of the chronic phase, a long-lasting 
asymptomatic phase of HIV infection during which the virus slowly replicates within CD4+ T 
cells, causing a gradual loss of CD4+ T cell numbers. When the number of CD4+ T cells reach 
below 200 CD4+ T cells/µL the immune system collapses causing a severe 
immunosuppression, leaving the patient at risk for opportunistic infections which mark the 
AIDS phase [44]. Fortunately, the number of HIV-positive subjects receiving ART increases 
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every year, resulting in that the frequency of HIV-positive subjects reaching the AIDS phase 
is steadily decreasing [37]. 
   
 
 
 
 
 
 
 
Figure 5. HIV-1 disease progression. HIV-1 infection goes through three distinct stages; acute infection, 
chronic infection and the AIDS phase.  
1.2.2.7 Elite control of HIV 
A group of HIV-positive individuals, called elite controllers, are able to spontaneously 
control their HIV infection by suppressing the virus to undetectable levels (< 50 copies/mL 
by standard methods) without the requirement for ART [49]. This group, which represents 
less than 1% of all HIV positive subjects, is highly interesting to HIV researchers because 
when the mechanisms behind their control are uncovered, it will likely boost the vaccine and 
cure development. A genome-wide association study identified HLA class I as a major 
genetic determinant of elite control [50] and the HLA-B*57 allele is strongly associated with 
elite control [51-53]. Additionally, elite controllers display an increased CD8+ T cell 
polyfunctionality and perforin production [54, 55]. However, elite controllers are a very 
heterogeneous group and the exact mechanisms behind this superior control remain unknown 
as do the reasons to why some elite controllers eventually lose the control of the virus. 
1.2.2.8 HIV treatment 
Ever since the beginning of the HIV/AIDS epidemic, research has been focused on finding a 
treatment or even better, a cure or a vaccine to stop the epidemic. To date, the cure and 
vaccine strategies have been unsuccessful. The first antiretroviral treatments against HIV 
were approved in 1987 when nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit 
the function of RT were developed, however drug resistance was quickly developed. In 1995 
the protease inhibitors (PI), which block the function of the viral protease and thus the 
maturation of viral particles were introduced and in 1996 the non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) another drug class that inhibits the function of RT were 
discovered. In 1996, it was found that when combining 2 NRTIs with a NNRTI or a PI in a 
three-drug regimen, the virus could be successfully repressed. This was the start of a new era 
with combination ART, enabling HIV-infected individuals to live near to full-length lives. 
Acute 
infection
Chronic 
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CD4+ T cells
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Since 1996 a number of new classes of drugs have been discovered; in 2003 the fusion 
inhibitors and entry inhibitors were developed. These drugs block the fusion of the viral 
particle and the host cell (blockade of gp41) or hinder the binding of HIV to receptors of host 
cells (e.g. CCR5 inhibitors). In 2007, integrase inhibitors that hinder the integration of viral 
DNA into host DNA were introduced. Today the “standard of care” treatment is two 
nucleoside/nucleotide inhibitors together with a third drug, either a PI, NNRTI, integrase 
inhibitor or a fusion/entry inhibitor.     
However, in resource-limited countries, not all HIV-infected individuals have access to ART 
and the treatment strategies may not always be optimal. Another concern is the increasing 
prevalence of acquired and transmitted drug-resistance, which may halt the progress made 
during the last decade [56]. Furthermore, in resource-limited settings, there is a problem with 
monitoring the patients, as the equipment required to measure viral loads, CD4 counts and 
other clinical parameters are not always available. Additionally, in many parts of the world 
HIV is still considered a stigma resulting in that many people do not know their HIV status. 
Therefore, in 2014 the UNAIDS launched a new strategy, named 90/90/90, meaning that by 
2020, 90% of all HIV-infected people will know their status, 90% of the diagnosed 
individuals will be on ART and 90% of the treated individuals will successfully repress the 
virus to undetectable levels. This was recently updated to 95/95/95 to be reached in 2030. In 
some countries 90/90/90 is already a reality and as treatment leads to an increased life 
expectancy, more and more people infected with HIV live near full-length lives. However, in 
many parts of the world there is still progress to be made. 
As the HIV-positive population is aging, physicians are faced with a new problem, which is 
treatment of the co-morbidities associated with long-term chronic HIV-infection. Today, the 
main object for the physicians is not to keep the patient alive, but to increase their quality of 
life [57, 58]. Even during successful treatment, HIV-positive individuals suffer from a 
number of co-morbidities such as cardiovascular disease and frailty syndrome which have 
been linked to the increased immune activation in HIV-infection [57]. Therefore, in order to 
stop the epidemic and limit the vast costs of HIV-treatment, a vaccine and/or a cure for HIV 
is still highly desirable. 
1.2.2.9 Immune activation during HIV infection 
During HIV infection the immune system becomes highly activated, a process that begins 
already during the acute phase of infection. Although a controlled immune activation is 
initially beneficial, a prolonged high-level immune activation is linked to disease progression 
[59]. The gastrointestinal tract is a major site for HIV replication and massive CD4+ T cell 
depletion during the early phase of infection [60-63]. This damages the gut mucosa, causing 
leakage of microbial products from the gut into the circulation, a process known as microbial 
translocation [64]. Translocation of microbial products causes activation of both adaptive and 
innate immune cells and is highly correlated to the levels of the activation markers CD38 and 
HLA-DR [59] on CD8+ T cells and to CD4+ T cell reconstitution following initiation of ART 
[64]. This is further supported by studies on African green monkeys that are a natural host for 
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SIV, as they display little immune activation and lack of microbial translocation. However 
they develop immune activation when their gut is damaged by experimental methods, 
supporting the role of microbial translocation in immune activation [65].  
Additionally, a process called pyroptosis was recently shown to be responsible for the death 
of abortively HIV-infected quiescent CD4+ T cells in the lymphoid tissues [66]. In contrast to 
apoptosis, it causes the dying cells to release their cytoplasmic contents and proinflammatory 
cytokines, thus recruiting new cells to the site [66]. These processes together cause T cell 
activation, which is initially beneficial, but becomes pathogenic during the chronic phase of 
the disease.  
1.2.2.10 Immune exhaustion during HIV infection  
The process of immune exhaustion was originally described in murine models of chronic 
viral infection [67] and later CD8+ T cell exhaustion was also described for HIV [68-71]. 
Exhausted CD8+ T cells upregulate inhibitory receptors such as PD-1, CD160, 2B4 [68-73] 
and TIGIT ([73] & Paper III) on their surface, a process linked to decreased functionality, 
proliferative potential and a transcriptional profile of T-betdimEomeshi ([68-71, 74] & Paper 
II) (Fig. 6). The functional properties are lost in a predetermined order. First, production of 
IL-2 is gone, followed by proliferative capacity and cytotoxicity. This is followed by loss of 
TNF production and in the later stages IFN-γ production. The very last stage of T cell 
exhaustion involves elimination of the exhausted cells [14] (Fig. 6). Although the functional 
capacity of HIV-specific CD8+ T cells is suboptimal, the exhausted cells have some residual 
functions as HIV escapes from CD8+ T cell immune pressure during chronic HIV infection 
[75, 76] and cells expressing PD-1 retain some functional capacity [77]. However there might 
be levels of exhaustion as high expression of PD-1 on CD8+ T cells is associated with a more 
exhausted phenotype than cells expressing low levels of PD-1 [78] and accumulation of 
several inhibitory receptors is linked to a more dysfunctional phenotype of virus-specific 
CD8+ T cells [71]. 
The process of T cell exhaustion is likely regulated at the transcriptional level, where the T-
box transcription factors T-bet and Eomes have been shown to play an important role. During 
a chronic viral infection T-bet expression decreases whereas Eomes expression increases 
resulting in that the majority of the cells are Eomeshi [19]. Furthermore, increased expression 
of T-bet has been linked to a better cytotoxic potential in elite controller subjects [79]. 
The upregulation of inhibitory receptors likely represents a way for the immune system to 
limit the immunopathology caused by prolonged antigen exposure (reviewed in [1, 15], 
however this comes at a cost as it leads to a suboptimal control of the virus due to the 
exhausted state of the virus-specific CD8+ T cells. 
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Figure 6. Immune exhaustion. A cleared viral infection results in a population of highly functional memory 
CD8+ T cells ready to combat re-infection. However, HIV causes a chronic infection during which virus persists, 
causing a massive inflammation and exhaustion of the CD8+ T cells. Exhausted CD8+ T cells lose their 
functional capacity, upregulate inhibitory receptors and gain a specific transcriptional profile. Adapted from [14]. 
Reprinted with permission. 
1.2.2.11 HIV latency 
One of the largest obstacles in obtaining a cure for HIV is the occurrence of latent infection in 
resting CD4+ T cells, resulting in a viral reservoir [80, 81]. Experiments in rhesus macaques 
have shown that seeding of the viral reservoir happens as early as three days after initial 
infection [82]. Latency is established when HIV infects a CD4+ T cell that is transitioning 
from an active effector state into a resting memory state, which is a part of the normal 
physiology of T cells (reviewed in [83, 84]) but HIV has also been shown to directly infect 
resting CD4+ T cells in vitro [85]. The latently infected cells do not produce any virus and 
will therefore not be recognized by the immune system. Furthermore, ART targets replicating 
virus, making it impossible to kill virus hidden in latently infected cells. Many of latently 
infected cells are present in secondary lymphoid tissues such as lymph nodes and GALT [80, 
81] and Tfh cells have been identified as one of the major cellular compartments of latent 
HIV-infection [8, 86], further complicating access to the latently infected sites.  Lately studies 
have been focusing on reactivating these resting cells in order to make the virus visible to the 
immune cells, a strategy named “shock-and-kill” [87] that will be discussed in section 1.3.3. 
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1.3 HARNESSING THE POWER OF T CELLS TO CURE DISEASE 
The importance of T cells in combating disease was discussed above. In this section I will 
discuss the use of T cells in immunotherapy after HSCT and in HIV vaccine and cure 
strategies. 
1.3.1. T cell immunotherapies after hematopoietic stem cell transplantation 
HSCT is associated with a high risk of relapse and complications caused by opportunistic 
viral infections. Furthermore, the recovery of T cell immunity takes up to two years after the 
HSCT, during which the patients are at an increased risk of obtaining opportunistic viral 
infections [88]. Therefore, donor lymphocyte infusions (DLI) are used to improve the 
restoration of T cell immunity after HSCT. DLI involves transferring T cells from the patient 
or from a donor into the patient after the HSCT in order to attack pathogens and/or malignant 
cells. The cells may also be altered before infusion and several strategies have been 
developed, for example genetically modified T cells that express chimeric antigen receptors 
(CARs) [89], pre-activation of the cells using CD3/CD28 beads [90], expansion of T cells 
against a specific virus or malignancy [91, 92] and stimulation of naïve T cells with viral or 
tumor antigens [93]. In order to make these approaches more effective and to increase the 
number of cells generated by these approaches, interleukins are commonly used in T cell 
expansions. IL-2 has been used in vitro and in clinical studies and increases the number of T 
cells [94, 95], however, IL-2 also expands Tregs [96], which dampen the desired immune 
responses. In order to avoid this IL-7 has been used to expand the cells without expanding 
Tregs, resulting in promising results in pre-clinical and clinical studies [97-99].  
It is of importance that the expanded cells that are transferred into the patient are of good 
quality and retain a functional capacity. Furthermore, the memory status of the cells is of 
importance, as the cells need to have effector functions as well as a capacity to form memory 
cells to combat re-emerging viral or tumor antigen. However, the exact fate of the injected 
cells in the human body is not known and therefore the capacity of T cells to form contacts 
with target cells and to eliminate the cells need to be further investigated in order to improve 
these treatment strategies.   
1.3.2. HIV vaccine strategies 
The optimal vaccine for HIV would be a prophylactic vaccine, however this has been 
difficult to develop due to the great genetic variability of HIV-1. The first HIV vaccine trials 
focused on creating neutralizing antibodies against HIV env. As T cells are the focus of this 
thesis, the B cell responses will not be discussed in detail, however successes have been made 
in the field of B cell responses against HIV as broadly neutralizing antibodies (bNAbs), able 
to neutralize a wide range of HIV-1 strains have been identified in a subset of HIV-infected 
subjects (reviewed in [100]). However the attempts to elicit these by vaccination have thus far 
not been successful (reviewed in [101, 102]). Many have instead looked into the T cell arm of 
the adaptive immune system, with the aim of creating T cell responses against viral proteins. 
The common goal for T cell based vaccines has been to find viral epitopes targeted by T cells 
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in conserved regions of the virus, i.e. regions in which escape mutations cannot occur without 
casing severe damage to the virus. In order to target a broad range of HIV-1 strains, viral 
peptides can be combined in to “mosaic” vaccines maximizing the coverage of T cell 
epitopes [103-105]. However, both the humoral and cellular arm of the adaptive immune 
system will be required in order to create a successful vaccine against HIV-1. 
The 2007 STEP trial and the 2013 HVNT trials both using adenovirus 5 vectors (Ad5) to 
carry HIV DNA, were terminated due to an increased risk of HIV-infection in the vaccinated 
population [106, 107]. However, the first success, although moderate, came in 2009, when 
the RV144 trial, based on a canary pox vector vaccine showed a vaccine efficacy of 31%. 
The RV144 was found to generate antibody dependent cellular cytotoxicity (ADCC) [108] 
and vaccination generated both T and B cell responses suggesting that both are required for 
an efficient vaccine [109]. In 2011 a paper was published on the success of a vaccine against 
SIV based on a CMV-vector in rhesus macaques. This vaccine had a 50% efficacy in 
monkeys lasting more than one year after immunization [110]. Interestingly, this vaccine had 
a capacity to induce broad CD8+ T cell responses restricted by both MHC class I and MHC 
class II alleles [111] and a later study showed that the broad CD8+ T cell responses were 
restricted by the non-classical HLA class Ib molecule HLA-E [112], providing a novel 
approach to HIV vaccine research. However, future studies will determine whether this new 
vaccine strategy will be efficient in human trials. 
Although a prophylactic vaccine has proven difficult to develop, important discoveries have 
been made on the way. Future vaccines against HIV will need to induce T cell responses 
against conserved regions of the virus and induce bNAbs or perhaps utilize a novel way of 
inducing immunity, such as the CMV-vector based vaccine strategy against SIV, as 
commonly used vaccination strategies have been proven unsuccessful. 
1.3.3. HIV cure strategies 
Since the start of the HIV epidemic, only one person, the “Berlin patient” has been cured 
from HIV infection [113, 114]. In this case, a HIV-infected man who developed leukemia 
was treated with a HSCT. The stem cell donor in this case had a homogenous deleterious 
mutation in the gene encoding CCR5, the main co-receptor for HIV entry, rendering the 
target cells to be protected from infection. The “Berlin patient” has remained completely free 
from detectable virus without ART and is considered cured from HIV. However, as HSCT is 
associated with a high risk for co-mortalities (section 1.2.1.2) and as most HIV-positive 
individuals on ART are healthy HSCT is not considered a feasible cure for HIV. 
Today, the shock-and-kill strategy [87] is one of the main approaches for a HIV cure. The 
“shock” part entails reactivating latently infected cells to start producing virus thereby 
making them visible for the immune system, whereas the “kill” part involves T cells and B 
cells that will clear the reactivated virus.  
In order to “shock” latently infected cells into producing virus, latency reversing agents such 
as histone deacetylase inhibitors (HDACi) have been used to increase the production of virus 
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in infected cells in vitro and in vivo, however, their effects do not last long-term [115-119]. 
Another obstacle is that virus-production currently is measured in peripheral blood, whereas 
many latently infected cells are present in the lymphoid tissues such as in lymph nodes [120] 
and GALT [121], making it difficult to measure the size of the latently infected reservoir. The 
future of this approach requires better methods for defining the latent reservoir and to 
optimize the efficiency of HDACi possibly by combining them with other classes of drugs 
that can reverse HIV latency (reviewed in [83]).   
The “kill” part is also complicated as the HIV-specific CD8+ T cells are exhausted and are 
not able to eliminate reactivated cells. Furthermore, the virus in the latently infected cells may 
contain escape mutations, resulting in that CD8+ T cells may not even recognize the re-
emerging virus [122]. As exhausted CD8+ T cells express inhibitory receptors, antibody 
blockade of these receptors has been developed to restore the function of HIV-specific cells. 
The first studies showed that blockade of PD-1 on HIV-specific CD8+ T cells ex vivo partly 
restored their functional capacity [68-70], followed by blockade of inhibitory receptors such 
as CD160 [72] and Tim-3 [123] on HIV-specific CD8+ T cells. Recently, co-blockade of PD-
1/PD-L1 and TIGIT ex vivo was shown to restore CD8+ T cell function better than single-
blockade of either PD-1/PD-L1 or TIGIT on cells from HIV-infected subjects and cancer 
patients [73, 124, 125], suggesting that co-blockade of several inhibitory receptors is likely to 
be beneficial in order to restore the function of HIV-specific CD8+ T cells. However, the 
TIGIT PD-1/PD-L1 co-blockade is not equally effective in all patients and in murine models, 
the level of PD-1 has been shown to impact the efficacy of PD-1/PD-L1 blockade as PD-1dim 
cells respond to treatment whereas PD-1hi cells do not [78] and for CD8+ T cells, PD-L1 
blockade efficiency is inversely correlated with viral loads [126]. Therefore the success of 
inhibitory receptor blockade may depend on the level of CD8+ T cell exhaustion, however, 
further trials are required to investigate this.   
Additionally, the transcriptional regulation of T cell exhaustion must be further investigated. 
In murine models, exhausted CD8+ T cells express a transcriptional profile of increased 
Eomes expression and decreased expression of T-bet, where the persistent antigen exposure 
drives the cells toward an Eomeshi profile [19]. This led us to investigate the role of T-bet and 
Eomes on CD8+ T cell exhaustion in HIV-infected subjects (Paper II). Additionally, T-bet is 
able to decrease PD-1 expression on CD8+ T cells by hindering transcription of the PD-1 
gene [20] whereas knockout of TIGIT increases T-bet expression on CD4+ T cells [127], 
showing a close link between inhibitory receptors and transcription factors involved in T cell 
differentiation. The question remains whether the transcriptional profile can be reversed in 
order to restore CD8+ T cell functionality. 
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2 AIMS 
 
Paper I: To use a microwell chip based screening method to investigate the migration 
patterns and cell-cell interactions of individual T cells cultured in IL-2 or a combination of 
IL-2 and IL-7.  
Paper II: To investigate the role of the T-box transcription factors T-bet and Eomes in CD8+ 
T cell exhaustion during HIV-1 infection. 
Paper III: To investigate the role of the TIGIT/CD226/PVR axis in CD8+ T cell exhaustion 
during HIV-1 infection  
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3 MATERIALS AND METHODS 
3.1 STUDY DESIGN AND PATIENT MATERIALS 
The study material in Paper I consisted of blood samples from 15 anonymous healthy donors 
Karolinska University Hospital Huddinge.  
In Paper II the patient material consisted of blood samples gathered at the HIV clinics at 
Karolinska University Hospital Huddinge and Venhälsan at Stockholm South General 
Hospital. Samples were collected from 52 individuals with chronic untreated HIV-infection 
and 12 HIV-infected individuals on long-term ART (> 10 years, undetectable VL for > 8 
years). Out of the untreated individuals, 24 were followed longitudinally at 0, 2, 4, 6, 8, 12-16 
weeks and 5-7 months after initiation of ART. Additionally, samples were collected from 20 
healthy donors. 
In Paper III blood samples were collected from HIV-infected individuals at the HIV clinics 
at Karolinska University Hospital Huddinge and Venhälsan at Stockholm South General 
Hospital. In total, 30 treatment naïve HIV-infected subjects (collected for the ACT4ART 
study) and 20 long-term treated (> 6 years ART, > 5 years with undetectable VL) and 26 
healthy controls were collected. Additionally peripheral blood mononuclear cell (PBMC) 
samples were obtained from the OPTIONS [128] (subjects with acute HIV-infection) and 
SCOPE [129] (elite controller subjects) cohorts at San Francisco Positive Health Program, 
San Francisco General Hospital. Furthermore, lymph node samples and paired blood samples 
were collected from 8 HIV-infected subjects at the Centre for Infectious Diseases Research, 
National Institute of Respiratory Diseases, Mexico City. Lymph nodes and blood samples 
were collected from 8 HIV-negative subjects at the University of Pennsylvania as negative 
controls. 
3.2 FLUORESCENCE MICROSCOPY 
In this thesis, confocal fluorescence microscopy was used to image the actions of T cells in a 
microwell chip. In a fluorescence microscope one or several lasers illuminate the sample in 
which the structure of interest has been labeled with fluorescent dyes or antibodies 
conjugated to fluorescent dyes. This results in that the fluorophore emits light at a specific 
wavelength that is picked up by the detectors connected to the microscope. By overlaying 
images from several channels, it is possible to create multi-color images where the location of 
each marker in relation to each other can be determined. Compared to conventional 
fluorescent microscopy, confocal microscopy increases the optical resolution by use of a 
pinhole that prevents detection of out-of-focus light. This technique enables imaging of focal 
planes making it possible to create three-dimensional reconstructions of the imaged samples. 
3.2.1 Imaging of T cells in a microwell-chip 
Single cell techniques for investigation of T cells are many, however flow cytometry and 
conventional time-lapse microscopy do not enable long-term studies of T cell migration 
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patterns or cell-cell interactions. With imaging flow cytometry, combining conventional flow 
cytometry and fluorescent microscopy, cell-cell interactions can be imaged, however, this 
only provides a snapshot of the events. Furthermore, conventional time-lapse microscopy 
does not allow for containment of the cells within a specific area, therefore cells migrate in 
and out of the imaged area, resulting in that their behavior cannot be followed for extended 
periods of time. In order to fully understand the heterogeneity of T cells and the cellular 
events taking place, a microwell-chip based imaging platform, enabling containment of cells 
in silicon microwells has been developed in our group to allow for analysis of the actions of 
NK cells at the single cell level for up to 48 hours [130-132].  
3.2.2 Microwell-chip 
The microwell-chip used in this thesis is a 2×2 cm silicon microchip mounted on a glass 
slide. The chip contains 81 wells, each with a size of 450×450 µm and a well depth of 300 
µm (Fig 7). This enables us to contain the cells within the wells in order to follow their 
migration pattern. Before use, the chip was sterilized in ethanol, after which the wells were 
coated with fibronectin to provide the cells with a surface suitable for cell migration. After 
this the chip was assembled in its holder, where it was held in place by magnets and a 
polydimethylsiloxane (PDMS) gasket. Finally the coating fluid was replaced with cell culture 
medium (Fig. 7).  
 
 
 
 
 
 
 
Figure 7. The microwell-chip. (A) Schematic picture of the microwell-chip setup, consisting of ; (1) custom-
made metal holder, (2) microwell-chip, (3) PDMS gasket and (4) lid. (B) Scanning electron microscopy image of 
a subsection of the microwell-chip.  
3.2.2.1 Cell culture 
PBMCs were separated from blood samples using density gradient centrifugation 
(Lymphoprep). T cells were subsequently isolated using anti-CD3/anti-CD28 beads, after 
which the cells were expanded for 7 days with the beads and addition of IL-2 or IL-2 + IL-7. 
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3.2.2.2 Staining of cells for flow cytometry analysis 
After 7 days in culture, extracellular staining of the cells was performed to measure 
occurrence of Tregs (CD4, CD25, CD39), γδ-T cells (TCR-γδ), memory phenotype 
(CD45RO, CCR7) and cell death (7-AAD).  
3.2.2.3 Staining of cells for microwell-chip analysis 
After 7 days in culture the cells were stained with fluorescent dyes in order to distinguish the 
two cell populations (effectors and targets). Calcein Green (AM) was used for target cells and 
Calcein Red-Orange for T cells. The target cells were seeded into the chip and when the wells 
contained ≈ 60 cells/well, cells that had not fallen into the wells were removed by changing 
the culture medium above the microwells and the remaining cells were allowed to adhere to 
the surface for 1 hour. Subsequently, the effector cells were seeded into the chip until ≈ 50 
cells/well were obtained after which abundant cells were removed by changing the culture 
medium above the microwell-chip.  
3.2.2.4 Time-lapse microscopy 
The microwell-chip was imaged in an inverted confocal fluorescence microscope with an 
environmental chamber kept at 37°C, 5% CO2 throughout the experiment. The microscope 
had a motorized stage allowing for automatic collection of images from selected wells at 
multiple positions. The pinhole was kept open to maximize the amount of light detected from 
the cells. For each experiment, four wells were imaged every 2 minutes for 7 hours with a 
20x objective.  
3.2.2.5 Image analysis 
Images were analyzed with ImageJ software (US National Institutes of Health, Bethesda, 
MD, USA). Each cell was tracked manually and interactions with target cells were scored. 
Each contact lasting ≥ 2 time points was counted as a true interaction. Cell death was defined 
by a loss of staining and/or blebbing or swelling of the cell membrane. Cells that could not be 
followed for at least 60 minutes were excluded from the analysis. 
3.3 FLOW CYTOMETRY 
Flow cytometry is a widely used tool to rapidly investigate multiple parameters of millions of 
heterogeneous immune cells. In a flow cytometer, fluorescently labeled cells are transported 
in a sheath fluid through a laser beam one by one. When hit by the laser the fluorochromes 
emit light at different wavelengths that travels through a set of filters and photomultiplier 
tubes to the detectors (Fig. 8). The method has developed quickly in the last decade, as in the 
beginning stages 3-4 fluorochromes could be used simultaneously, whereas today it is 
theoretically possible to use up to 18 colors in the more advanced flow cytometers, even 
though most panels are restricted to 15-16 colors due to overlaps in the emission spectra 
between fluorochromes. Mass cytometry, using antibodies labeled with isotopes instead of 
fluorescent dyes allows for detection of up to 40 markers simultaneously (reviewed in [133]). 
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Here, the mass of the isotopes is measured, resulting in narrower peaks, allowing for multiple 
markers to be analyzed simultaneously without the risk of overlap. In this thesis, multi-color 
(up to 16 colors) flow cytometry has been used to measure functional and phenotypic markers 
of human T cells. 
 
 
 
 
 
 
 
 
 
Figure 8. Image of the basic components of a flow cytometer. Fluorescently labeled cells pass through a laser 
beam, sending out light that passes through a set of mirrors and filters on its way to the detectors that converts 
the light into an electronic signal that is sent to a computer. 
3.3.1 Peptide stimulations and intracellular staining of cells 
In Paper II and Paper III, PBMCs (1-2x106/well) were stimulated with overlapping HIV 
Gag-p55 and HCMV pp65 peptides (15-mers overlapping by 11 amino acids at a 
concentration of 1 µg/mL) to detect HIV and CMV specific responses or in medium alone for 
negative controls in the presence of anti-CD107a antibody (detection of degranulation) and 
the protein transport inhibitors monensin and Brefeldin A. The cells were incubated for 10 
hours at 37°C 5% CO2 after which they were stained with extracellular antibodies and 
LIVE/DEAD Aqua amine dye solution. When performing extracellular staining only, cells 
were subsequently washed and fixated in a PBS solution containing 1% paraformaldehyde. In 
order to stain for cytoplasmic proteins and transcription factors, the cells were fixated and 
permeabilized using a FoxP3 transcription factor buffer kit, followed by staining with 
intracellular markers after which the cells were washed and resuspended in PBS + 1% 
paraformaldehyde. 
3.3.2 Analysis of flow cytometry data 
PBMCs and lymph node mononuclear cells (LNMCs) were analyzed on a modified 4-laser 
LSR Fortessa (BD Biosciences). Single-stain compensation controls were performed with 
antibody capture beads (BD Bioscience). Flow cytometry data was analyzed with FlowJo 
8.8.7 (Treestar). Fluorescence minus one (FMO) gating strategies were use to set the manual 
gates when applicable. A virus-specific response was considered positive if ≥ 0.05% of the 
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cells produced IFN-γ after a background reduction and if the virus-specific response was 
larger than twice the negative background signal. 
3.4 BIOINFORMATICS 
In order to interpret and visualize the complex data acquired from flow cytometry analysis, 
bioinformatics is useful. In this thesis we have used three bioinformatics methods; SPICE 
(Paper II & III), principal component analysis (Paper II) and viSNE (Paper III) to analyze 
the data (Fig. 9). 
 
 
 
 
 
 
 
 
 
 
Figure 9. Bioinformatics. (A) SPICE plot depicting combinations of 4 inhibitory receptors (2B4, CD160, PD-1 
& TIGIT) on HIV-specific CD8+ T cells in three groups of patients (HIV+ART-, HIV+ART+ & EC). (B) PCA 
plot depicting HIV-specific (orange) and CMV-specific (green) CD8+ T cell populations combining functional 
and inhibitory markers (n=256). (C) viSNE analysis of CD8+ T cell maturation phenotype (left plot) and 
intensity of TIGIT expression on CD8+ T cell maturation phenotypes (right plot). 
3.4.1 SPICE 
SPICE (Simplified Presentation of Incredibly Complex Evaluations) is a freely available 
software [134] used to present complex multi-parameter flow cytometry data in a more 
comprehensible manner. In Paper II and Paper III, SPICE was used to create graphs of pre-
gated (Boolean gating) combinations of T cell functions and of inhibitory receptor expression 
and to compare these between groups. 
3.4.2 Principal component analysis (PCA) 
When acquiring large amounts of multivariate data, statistical methods able to reduce the 
dimensionality of the data are required. Principal component analysis (PCA) is an 
unsupervised statistical method that reduces the dimensionality of the data by projecting 
complex data into two dimensions while maintaining single-cell resolution. In Paper II, PCA 
was used to compare HIV- and CMV-specific CD8+ T cells pre-gated (Boolean gating) for 
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functional and inhibitory receptor characteristics in order to see how the groups were 
distributed in relation to each other. 
3.4.3 viSNE 
viSNE is another tool for visualization of multivariate single-cell data, in this case based on 
the t-Distributed Stochastic Neighbor Embedding (t-SNE) algorithm. viSNE interprets 
complex single-cell data in order to find the best two-dimensional representation while 
preserving the local and global geometry of the data [135].  In Paper III, viSNE was used for 
plotting the expression pattern and intensity of inhibitory/stimulatory receptors on naïve and 
memory subsets of CD8+ T cells. 
3.5 STATISTICS 
In all papers, statistical analysis was performed using either GraphPad Prism, Matlab, R 
environment or SPICE software. Mann-Whitney U test was used to compare two unmatched 
groups of samples and Wilcoxon-matched pairs signed rank test was used to compare two 
matched groups of samples.     
Additionally, in Paper I, Chi-square test was used to evaluate cell-cell contacts, cell division 
and cell death. In Paper II and Paper III, correlation analysis was done using Spearman 
rank tests. One-way ANOVA, followed by Kruskall-Wallis non parametric Dunn’s multiple 
comparison tests were performed to compare 3 or more groups and permutations tests were 
performed on data from SPICE. In Paper II, data from Boolean combinations were analyzed 
by PCA. The Kolmogorov-Smirnov test was used to test the null hypothesis that the groups 
from PCA were drawn from the same distribution. In Paper III viSNE analysis was 
performed in order to visualize complex expression patterns of cell surface markers on CD8+ 
T cell subsets.  
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4 RESULTS AND DISCUSSION 
The main aim of this work was to gain a deeper knowledge of human T cell functions, such 
as migration, cell-cell interactions, memory differentiation and cytotoxic capacity and of the 
mechanisms that impair these properties. In this thesis two single-cell analysis methods have 
been used to investigate the functional properties of human T cells; imaging in a microwell-
chip and multi-color flow cytometry. This section will present and discuss the results from 
these studies.   
4.1 MICROWELL CHIP BASED IMAGING OF T CELLS CULTURED WITH IL-2 
OR IL-2+IL-7 
After a HSCT patients are at risk for relapse and acquiring opportunistic viral infections. DLI 
of ex vivo or modified T cells can be used to aid in the recovery of T cell immunity in order to 
decrease the risk of complications. However, there is a need to speed up the expansion 
process and to improve the safety of the protocols. In Paper I, a novel microchip based 
screening method was used to monitor the migration and cell-cell interaction patterns of T 
cells expanded in two different conditions; IL-2 alone or a combination of IL-2 and IL-7.   
Cells from healthy blood donors were expanded for 7 days together with anti-CD3 and anti-
CD28 beads in order to induce cell expansion. In addition, IL-2 alone or in combination with 
IL-7 was added to the cells. After 7 days the cells were stained for flow cytometry analysis or 
microwell-chip based imaging.  
In 7 out of 12 subjects addition of IL-7 gave a higher fold expansion compared to IL-2 alone 
however, this was not statistically significant. These data were not in line with previous data 
based on cord-blood derived cells, where addition of IL-7 resulted in a significant increase in 
expansion compared to IL-2 alone [136]. The difference might be due to different 
glycosylation patterns of IL-7 as we used CYT107a produced in the CHO cell line whereas 
Berglund et al. [136] used IL-7 produced in E. coli. Furthermore, cord-blood derived T cells 
have a more naïve phenotype than PBMCs from adult subjects, which may alter the response 
to cytokine exposure. The flow cytometry data did not show any differences between the 
groups in terms of T cell maturation phenotypes. From the microwell-chip data we found that 
neither the migration speed nor the number or the duration of cell-cell interactions differed 
between cells cultured in IL-2 + IL-7 compared to cells treated with IL-2 only. Interestingly, 
addition of IL-7 significantly reduced cell death in the microwell-chip, although it had no 
effect on mitosis, suggesting that IL-7 renders the cells more resistant to cell death. However, 
this could not be corroborated by flow cytometry, where few dead cells were found. The 
differences might be a result of the definition of cell death as in the microscope, cell death 
was defined as a blebbing or swelling of the cell membrane, whereas in the flow cytometry 
analysis cell death was measured by 7-AAD and Annexin V. Additionally, in the microwells 
dying cells are imaged continuously whereas dying cells in flow cytometry analysis may be 
disintegrated resulting in that they are lost during wash steps or that they due to their small 
size are discarded as cellular debris. 
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In summary these data show that IL-7 in combination of IL-2 is beneficial when preparing T 
cells for immunotherapy and that the microwell-chip based method is suitable for monitoring 
of T cells. 
4.2 FLOW CYTOMETRY ANALYSIS OF HIV-SPECIFIC CD8+ T CELLS  
During the course of HIV-1 infection CD8+ T cells become exhausted due to the constant 
antigen burden, resulting in a loss of functional capacity and an upregulation of inhibitory 
receptors. This process that has been investigated in Paper II and Paper III.  
In murine models the transcription factors T-bet and Eomes are differentially expressed in 
exhausted and functional CD8+ T cells [19], however their role in exhaustion of human HIV-
specific cells is not known. Therefore, in Paper II, we investigated whether T-bet and Eomes 
are transcriptionally linked to CD8+ T cell exhaustion in HIV-1 infection. 
Samples from treatment-naïve HIV-infected subjects and long-term treated HIV-infected 
subjects were analyzed with flow cytometry. We found that T-bet and Eomes were inversely 
expressed on CD8+ T cells in HIV-infected subjects, resulting in a T-betdimEomeshi profile 
that was linked to single- and triple expression of the inhibitory markers PD-1, CD160 and 
2B4 on bulk and HIV-specific CD8+ T cells. The vast majority of HIV-specific CD8+ T cells 
were T-betdimEomeshi whereas CMV-specific CD8+ T cells in the same subjects had a more 
balanced expression of T-bet and Eomes. Furthermore, the frequency of T-betdimEomeshi cells 
was negatively correlated with the polyfunctional capacity (IFN-γ, TNF, CD107a, Granzyme 
B & IL-2) of the cells. Subjects initiating ART were followed longitudinally for 6 months, 
however the expression of inhibitory receptors and the transcriptional profile of T-
betdimEomeshi remained elevated even after successful ART. In patients that had been on 
ART for more than 10 years, the expression of T-betdimEomeshi cells was significantly 
decreased compared to short-term treated subjects, however not to the levels seen for CMV-
specific cells in the same subjects. 
The T-betdimEomeshi profile remained even after long-term ART, suggesting that this 
exhausted transcriptional profile is imprinted on the HIV-specific cells and is not reverted by 
removing the antigen. Approaches to restore functionality to HIV-specific CD8+ T cells will 
likely require modulation of T-bet and/or Eomes expression, as T-bethi cells are associated 
with a better cytotoxic capacity [79] and T-bet promotes transcription of Granzyme B and 
perforin in T cells [137], whereas Eomes is highly expressed in exhausted and more early 
differentiated T cells (Paper II). Recently, in a murine model of cancer, inhibitory receptor 
co-blockade induced T-bet expression on tumor-infiltrating CD8+ T cells [138], showing that 
the transcriptional profile can be reversed.  Furthermore, this T-bet upregulation was 
associated with differentiation to an effector phenotype and IFN-γ production by tumor-
specific CD8+ T cells [138], however, additional studies are required to confirm this effect on 
human CD8+ T cells. Additionally, T-bet has been shown to bind the PD-1 promoter region 
and is able to repress PD-1 expression in mice [20], and T-bet expression was induced by 
blockade of TIGIT on human CD4+ T cells, suggesting that these processes can be altered by 
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treatment. In summary, Paper II demonstrates that CD8+ T cell exhaustion is driven at the 
transcriptional level and partly explains why HIV-specific CD8+ T cells cannot fully control 
viral replication without the presence of ART, suggesting that modulation of T-bet and/or 
Eomes expression is likely required to reinvigorate HIV-specific CD8+ T cell responses.  
The upregulation of inhibitory receptors on CD8+ T cells is linked to a loss of cytokine 
production, cytotoxicity and proliferative capacity. Therefore, in Paper III, we continued the 
investigation of the effects of inhibitory receptor expression on HIV-specific CD8+ T cell 
responses by investigating the role of the inhibitory receptor TIGIT in HIV-infected subjects.  
Samples from treatment-naïve HIV-positive subjects, HIV-positive subjects on long-term 
ART, acutely infected subjects and elite controllers were analyzed with flow cytometry. We 
found an increased expression of TIGIT on bulk and HIV-specific CD8+ T cells that was 
linked to expression of PD-1, CD160 and 2B4. On HIV-specific cells the increase in TIGIT 
expression was coupled to a decreased expression of the co-stimulatory receptor CD226. 
Furthermore, a high level of TIGIT expression (TIGIThi) was less common in elite controller 
subjects, compared to treatment naïve and long-term treated subjects and the TIGIThi cells 
were linked to a decreased functional capacity (IFN-γ, TNF, granzyme B & CD107a). 
Additionally, TIGIThi cells had a transcriptional profile of T-betdimEomeshi, which in Paper 
II was linked to a highly exhausted phenotype. As TIGIT needs to bind its ligand, PVR, in 
order to inhibit T cell function, we next measured PVR expression on CD4+ T cells in blood 
and lymph node. PVR expression was elevated on CD4+ T cells, especially Tfh cells, in HIV-
infected subjects compared to healthy controls both in lymph node and blood.   
The TIGIT/CD226 receptor pair shares many qualities with the CTLA-4/CD28 
inhibitory/stimulatory receptor pair. Both CTLA-4 and TIGIT have a higher affinity for 
binding the ligands CD80/CD86 and PVR, than their respective complementary co-
stimulatory receptors CD28 and CD226 and thus outcompetes them in binding capacity [16, 
139]. In addition, both CTLA-4 and TIGIT can downregulate the expression of their 
respective co-stimulatory receptors, dampening the activating signals [125, 140], confirming 
the importance of the TIGIT/CD226 axis on CD8+ T cell function. Blockade of inhibitory 
receptors such as PD-1, CD160 and TIGIT using antibodies has been shown to increase the 
functional capacity of HIV-specific cells [68-70, 72, 73], suggesting a potential mechanism to 
restore the function of exhausted CD8+ T cells. However, the increased frequency of TIGIThi 
cells among the HIV-specific cells suggests that the increased expression of TIGIT might 
make restoration of their functional capacity problematic. In murine models, PD-1hi cells do 
not respond to PD-1/PD-L1 blockade, whereas PD-1dim cells do [78], suggesting that an 
increased expression of inhibitory receptors, likely due to prolonged antigen-exposure drives 
the cells towards a highly exhausted phenotype. Interestingly, expression of the 
TIGIT/CD226 ligand, PVR, was increased on Tfh cells, which are one of the major sources 
of productive and latent HIV-1 infection [8], suggesting that PVR is upregulated on HIV-
infected CD4+ T cells. As CD8+ T cells have a very restricted access to the B cell follicles 
where Tfh cells reside [141], it is likely they cannot reach the infected cells. In a recent study 
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in elite controller rhesus macaques the B cell follicles were the only sites in the lymph node 
with active HIV replication, likely due to that SIV-specific CD8+ T cells could not reach 
these areas [142]. Additionally, our data suggests that even if CD8+ T cells are able to enter 
the B cell follicles, they might not be able to eliminate infected cells due to the upregulation 
of TIGIT and PVR during HIV infection, as studies of NK cells have shown that TIGIT/PVR 
binding likely hinders their cytotoxic capacity [143]. In summary, our data provides evidence 
that the altered TIGIT/CD226/PVR axis needs to be considered for future approaches aimed 
at restoring the function of HIV-specific CD8+ T cells.  
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
In this thesis, single cell methods have been used to monitor the actions of human T cells 
with the aim to understand the mechanisms of T cell function/dysfunction.  
Because of their heterogeneous nature, single cell studies of T cells are of importance to 
understand their functions. In Paper I, a microwell chip based method enabling single cell 
tracking of T cell migration was used. In Paper II and III, multi-color flow cytometry was 
used to measure function, phenotype, level of immune activation/exhaustion, and 
transcriptional activity on individual CD8+ T cells.  
In paper I, we found a decrease in cell death of T cells that were expanded with a 
combination of IL-2 and IL-7 when cultured in a microwell chip. These findings suggest that 
addition of IL-7 to the current T cell expansion protocol would make the cells more resistant 
to cell death. Furthermore, this study shows that the microwell chip is well suited for analysis 
of human T cells. As methods for imaging the behavior of human cells in vivo are not 
available, there is a need for in vitro models in which the behavior of human T cells can be 
tracked. T cells have been imaged in vivo in murine models (reviewed in [144]), providing 
important information on the behavior of T cells, however mice are not men, and although 
many similarities exist, we cannot be certain that what is seen in mice is true for humans. 
Therefore, filling the microwell-chip with a gel mimicking human tissue would allow for 
imaging of cell migration in vitro within an environment that mimics conditions found in the 
human body. Although this would also be a model, it might provide new insights into human 
T cell behavior and allow us to use a more controlled platform, which is easily altered, 
allowing for comparison of several conditions simultaneously. 
In Paper II and Paper III, the exhausted phenotype of CD8+ HIV-specific cells was 
associated with a decreased functional capacity of the cells and a transcriptional phenotype of 
T-betdimEomeshi. The results from Paper II show that even in HIV-infected subjects on long-
time ART, the inverse transcriptional profile of T-bet and Eomes does not return to levels 
seen in CMV-specific cells. Reversal of the T-betdimEomeshi transcriptional profile of 
exhausted CD8+ T cells would require induction of T-bet expression, while decreasing 
expression of Eomes. Future studies will need to further investigate the synergistic effects of 
co-blockade of inhibitory receptors such as TIGIT, PD-1, CD160 and 2B4 on CD8+ T cell 
function and phenotype. Furthermore, the effects of inhibitory receptor co-blockade on the 
transcriptional profile need to be assessed. Additionally, the phenotype and functional 
characteristics of CD8+ Tcells that are restored by such treatment need to be investigated, as 
highly exhausted HIV-specific cells expressing high levels of inhibitory receptors ([70] & 
Paper II & Paper III) may not respond to treatment as seen for murine PD-1hi cells [78].  
In Paper III, the increased expression of TIGIT on HIV-specific cells was linked to a 
downregulation of CD226 on HIV-specific CD8+ T cells and an upregulation of PVR on Tfh 
cells. Additional studies will need to investigate whether TIGIT+ HIV-specific CD8+ T cells 
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are capable of eliminating HIV-infected cells with an increased expression of PVR, as their 
interaction may hinder CD8+ T cell cytotoxicity. The cytotoxic capacity of TIGIT+ cells may 
be restored by antibody-blockade of TIGIT in combination with other inhibitory receptors (as 
discussed in the results and discussion section). Furthermore, as the B cell follicles are a 
major reservoir for latent and productive HIV infection, future studies will need to further 
investigate the presence and function of the few CXCR5+ CD8+ T cells in the B cell follicles 
and to find a way for additional HIV-specific CD8+ T cells to gain access to the B cell 
follicles. Furthermore, the safety of such a procedure needs to be assessed in order to avoid 
cytotoxicity against non-HIV-infected cells.  
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